KR960700692A - 면역 반응의 강화 방법(immunological response potentiation process) - Google Patents

면역 반응의 강화 방법(immunological response potentiation process) Download PDF

Info

Publication number
KR960700692A
KR960700692A KR1019950703557A KR19950703557A KR960700692A KR 960700692 A KR960700692 A KR 960700692A KR 1019950703557 A KR1019950703557 A KR 1019950703557A KR 19950703557 A KR19950703557 A KR 19950703557A KR 960700692 A KR960700692 A KR 960700692A
Authority
KR
South Korea
Prior art keywords
feature
cell
epitopes
antigen
synthetic
Prior art date
Application number
KR1019950703557A
Other languages
English (en)
Other versions
KR100372375B1 (ko
Inventor
부르노 간더
지암 피에트로 코라딘
잉 멘
콜라우디오 토마신
한스 피터 머클
Original Assignee
베.요트.보러·아.에르.로렌츠
지에프에프 게셀샤프트 쥬우르 포데룽 데르 인다스트리-오리엔티에르텐 포충
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베.요트.보러·아.에르.로렌츠, 지에프에프 게셀샤프트 쥬우르 포데룽 데르 인다스트리-오리엔티에르텐 포충 filed Critical 베.요트.보러·아.에르.로렌츠
Publication of KR960700692A publication Critical patent/KR960700692A/ko
Application granted granted Critical
Publication of KR100372375B1 publication Critical patent/KR100372375B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Abstract

합성되었거나 생리적으로 상승되어 면역성이 낮은 항원을 강화하기 위해 면역반응 강화 방법이 개발되었다. 항원은 생물분해서 미립자속으로 투입되고, 이 항원을 함유한 미립자는 다시 매개 속으로 확산되는데 이 분산매가 주사로 투여될 때 수양성 항원용액과 비교해 볼때 더욱 강화된 항체 즉 TB-임파구세포와 TC-임파구 세포반응을 촉진시킨다. 면역강화의 정도는 적어도 IFA방식에 의해 얻어진 면역강화 정도와 비교될 수 있다. 선형 B-TH-세포 에피토프, 선형 TC-세포-에피토프, 이 두가지 에피토프의 이합체(dimer)와 다합체(multimer) 등은 그 결합물과 마찬가지로 면역성이 약한 항원으로 이용된다. 미립자는 다양한 습윤제(wettabilities), 팽창제를 혼합시킴으로서 릴리스(release)와 생물분해 시간을 달성할 수 있다. 이 공정은 바이러스, 박테리아, 원충 또는 종양세포로 인해 발병된 인간과 동물의 질병을 면역시키는데 효력을 발휘한다.

Description

면역 반응의 강화 방법(IMMUNOLOGICAL RESPONSE POTENTIATION PROCESS)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 합성항원에 대한 사람과 동물의 면역반응의 강화를 위한 방법은 다음과 같은 특징을 가진다; 합성항원은 먼저 분해성 구형 미립자에 투여시킨다. 그후에 합성항원을 함유한 미립자는 분산매속에서 현탁된다. 이 조합체를 주사로 투여하여 강화된 면역반응이 일어난다.
  2. 청구의 범위 제1항에 따른 방법의 특징은 합성항원으로 적어도 하나의 B-세포 에피토프와 TH-세포-에피토프를 가진 단순한 체인(chain)로 구성된 결합물을 사용한다는 점이다.
  3. 청구의 범위 제1항에 따른 방법의 특징은 합성항원으로 반복적 공유결합된 B-세포-에피토프와 TH-세포-에피토프로 구성된 결합물을 사용한다는 점이다.
  4. 청구의 범위 제1항에 따른 방법의 특징은 합성항원으로 세균독성 T-세포-에피토프(TC)로 구성된 혼합물을 사용한다는 점이다.
  5. 청구의 범위 제1항에 따른 방법의 특징은 합성항원으로 적어도 하나의 TH-에피토프와 적어도 하나의 TC-에피토프의 결합물을 사용한다는 점이다.
  6. 청구의 범위 제1∼5항 까지의 방법의 특징은 합성항원의 원충, 바이러스, 박테리아 또는 종양세포에서 유래한 B-세포 에피토프와 T-세포-에피토프를 함유하고 있다는 것이다.
  7. 청구의 범위 제1∼5항에 따른 방법의 특징은 합성항원의 원충, 바이러스, 박테리아, 종양세포 또는 이러한 것들의 임의적 결합물에서 나온 B-세포 에피토프와 T-세포-에피토프를 포함하고 있다는 점이다.
  8. 청구의 범위 제1∼7에 따른 방법의 특징은 구형미립자가 적합한 분해성 생물 폴리어로 만들어졌다는 것이며, 생물폴리어는 폴리(유산), 폴리(글리코산), 폴리(유산-CO 글리코산), 폴리오르토에스레(poly orthoester) 및 다무수화합물(poly anhydrie)의 그룹에서 유래한다는 점이다.
  9. 청구의 범위 8에 따른 방법의 특징은 생물폴리어가 적어도 2개의 서로 다른 그룹에서 유래한다는 점이다.
  10. 청구의 범위 제1∼9항에 따른 방법의 특징은 수성이나 유성의 레시틴 용액이나 또는 수성-유성 레시틴-유탁액이 분산매로 사용된다는 점이다.
  11. 청구의 범위 1∼9항에 따른 방법의 특징은 분산매로서 미소 유제를 사용한다는 점이다.
  12. 바이러스, 박테리아, 원충, 종양세포에 의해 발생된 질병에 대해 인간과 동물의 면역화에 청구의 범위 제1∼11항에 따른 방법을 적용한다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950703557A 1993-12-23 1994-12-23 면역반응의강화방법 KR100372375B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH384993 1993-12-23
CH3849/93-6 1993-12-23

Publications (2)

Publication Number Publication Date
KR960700692A true KR960700692A (ko) 1996-02-24
KR100372375B1 KR100372375B1 (ko) 2003-04-21

Family

ID=4264801

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950703557A KR100372375B1 (ko) 1993-12-23 1994-12-23 면역반응의강화방법

Country Status (12)

Country Link
US (1) US6596278B2 (ko)
EP (1) EP0686030B1 (ko)
JP (1) JPH08507088A (ko)
KR (1) KR100372375B1 (ko)
CN (1) CN1120809A (ko)
AT (1) ATE199316T1 (ko)
AU (1) AU1217395A (ko)
CA (1) CA2156718A1 (ko)
DE (1) DE59409668D1 (ko)
DK (1) DK0686030T3 (ko)
ES (1) ES2156932T3 (ko)
WO (1) WO1995017167A1 (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
EP0965336A1 (en) 1995-11-09 1999-12-22 Microbiological Research Authority Microencapsulated DNA for gene therapy
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
WO1999002183A2 (en) * 1997-07-10 1999-01-21 Ctl Immunotherapies Corporation A method of inducing a ctl response
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
WO1999065531A1 (en) 1998-06-18 1999-12-23 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
ATE452651T1 (de) 1998-09-01 2010-01-15 Merrion Res Iii Ltd Orale impfstoff-zusammensetzung
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
EP2351576A1 (en) * 2004-12-29 2011-08-03 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
US8202523B2 (en) * 2005-09-22 2012-06-19 ProSci, Inc. Glycosylated polypeptides produced in yeast mutants and methods of use thereof
JP2009512729A (ja) * 2005-10-24 2009-03-26 スタヴァル ファーマ リミテッド 菌類及び細菌を処理、抑制、殺滅する方法
AR064862A1 (es) * 2007-01-15 2009-04-29 Glaxosmithkline Biolog Sa Proteinas de fusion que comprenden un antigeno de rechazo tumoral prame (dage)
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
EP2575869B1 (en) * 2010-06-04 2017-07-26 Flow Pharma Inc. Peptide particle formulation
CN102901814B (zh) * 2012-07-12 2014-11-26 浙江大学 莠去津分子印迹金标试纸条及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599230A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US5417986A (en) 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5762965A (en) * 1984-03-16 1998-06-09 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradble-biocompatible microspheres
US4803070A (en) 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US5008116A (en) * 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
JP3233402B2 (ja) 1989-11-13 2001-11-26 サイオス ノバ インコーポレイテッド 物質の制御送達用のリポスフェア
AU8303691A (en) * 1991-04-24 1992-12-21 United States Of America, As Represented By The Secretary Of The Army, The Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US6004763A (en) 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
WO1994015635A1 (en) * 1993-01-11 1994-07-21 Dana-Farber Cancer Institute Inducing cytotoxic t lymphocyte responses
US5879687A (en) * 1994-04-22 1999-03-09 Corixa Corporation Methods for enhancement of protective immune responses
DK0991403T3 (da) 1997-01-30 2003-07-28 Chiron Corp Anvendelse af mikropartikler med adsorberet antigen til stimulering af immunresponser
US6312731B1 (en) 1997-08-29 2001-11-06 Southern Research Institute Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
PT1042001E (pt) 1997-12-16 2002-09-30 Chiron Corp Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua
ATE322285T1 (de) 1998-09-01 2006-04-15 Elan Corp Plc Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff- zusammensetzungen dazu

Also Published As

Publication number Publication date
DE59409668D1 (de) 2001-04-05
EP0686030B1 (de) 2001-02-28
AU1217395A (en) 1995-07-10
CN1120809A (zh) 1996-04-17
CA2156718A1 (en) 1995-06-29
US20020041879A1 (en) 2002-04-11
ES2156932T3 (es) 2001-08-01
US6596278B2 (en) 2003-07-22
EP0686030A1 (de) 1995-12-13
ATE199316T1 (de) 2001-03-15
WO1995017167A1 (de) 1995-06-29
KR100372375B1 (ko) 2003-04-21
DK0686030T3 (da) 2001-06-25
JPH08507088A (ja) 1996-07-30

Similar Documents

Publication Publication Date Title
KR960700692A (ko) 면역 반응의 강화 방법(immunological response potentiation process)
McComb et al. Introduction to the immune system
Miller et al. Nonviable bacterial antigens administered with IL-12 generate antigen-specific T cell responses and protective immunity against Listeria monocytogenes.
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
DK0678034T3 (da) Induktion af cytotoksiske T-lymfocytreaktioner
CA2314934A1 (en) Use of microparticles combined with submicron oil-in-water emulsions
ES2196385T3 (es) Sistema de liberacion de microparticulas dirigible biodegradables.
RU2009113834A (ru) Микрофлюидизированные эмульсии "масло в воде" и композиции вакцины
DK0654086T3 (da) Vacciner mod Aujeszky's sygdom og andre dyresygdomme indeholdende mutanter af pseudo-rabies-virus
ATE320792T1 (de) Mikropartikel zur verabreichung von heterologen nukleinsäure
TR199800607T1 (xx) Dendritik h�cre uyar�c� fakt�r�.
CN1030019A (zh) 疫苗及其制备方法
DE69836268D1 (de) Immunverstärkende Zusammensetzung in fester Verabreichungsform mit Kollagen oder Polydimethylsiloxan als Trägersubstanzen
AU6714290A (en) Method of treating infectious bursal disease virus
GB2160312A (en) Adjuvant for immunisation
ATE322285T1 (de) Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff- zusammensetzungen dazu
Terry Ulrich MPL® immunostimulant: adjuvant formulations
Smith et al. IgE production in five inbred rat strains following immunization with alum-precipitated egg albumin
Muschel et al. Effect of anti-lymphocyte serum on natural antibody
Janeway Jr How the immune system discriminates infectious nonself from noninfectious self
Gillen et al. Wise Blood: Antibodies, the Principle of Overcoming in Disease (Part 2)
JPH05255112A (ja) アジュバント組成物
Stewart-Tull Symposium on immunological adjuvants
JP2007045730A (ja) 免疫誘導能増強方法

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20060126

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee